abo2102
Advanced / Metastatic Solid Tumor
Suzhou Abogen Biosciences Co., Ltd.vaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Advanced / Metastatic Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Suzhou Abogen Biosciences Co., Ltd. | Phase 1 | CC |
Botensilimab Stingray Therapeutics | Phase 1 | CC |
Balstilimab Stingray Therapeutics | Phase 1 | CC |
SR-8541A Stingray Therapeutics | Phase 1 | CC |
Same molecule, other indications
abo2102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →